BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 11126446)

  • 1. The neurosurgical management of prolactinomas.
    Gökalp HZ; Deda H; Attar A; Uğur HC; Arasil E; Egemen N
    J Neurosurg Sci; 2000 Sep; 44(3):128-32. PubMed ID: 11126446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery.
    Amar AP; Couldwell WT; Chen JC; Weiss MH
    J Neurosurg; 2002 Aug; 97(2):307-14. PubMed ID: 12186458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery.
    Han YL; Chen DM; Zhang C; Pan M; Yang XP; Wu YG
    Medicine (Baltimore); 2018 Nov; 97(45):e13198. PubMed ID: 30407358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Microsurgical Sublabial Approach (MSA) Versus Endoscopic Endonasal Approach (EEA) for the Treatment of Pituitary Adenomas Based on Radiological and Hormonal Outcome.
    Mattogno PP; Mangiola A; Lofrese G; Vigo V; Anile C
    Acta Neurochir Suppl; 2017; 124():101-106. PubMed ID: 28120060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?
    Turner HE; Adams CB; Wass JA
    Eur J Endocrinol; 1999 Jan; 140(1):43-7. PubMed ID: 10037250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V; Raftopoulos C; Maiter D
    Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of surgery for the treatment of prolactinomas.
    van't Verlaat JW
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactinomas in children under 14. Clinical presentation and long-term follow-up.
    Liu Y; Yao Y; Xing B; Lian W; Deng K; Feng M; Wang R
    Childs Nerv Syst; 2015 Jun; 31(6):909-16. PubMed ID: 25771923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and treatment of pituitary adenomas.
    Chanson P; Salenave S
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medically treated prolactin-secreting pituitary adenomas: when should we operate?
    Vale FL; Deukmedjian AR; Hann S; Shah V; Morrison AD
    Br J Neurosurg; 2013 Feb; 27(1):56-62. PubMed ID: 22938595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up.
    Feigenbaum SL; Downey DE; Wilson CB; Jaffe RB
    J Clin Endocrinol Metab; 1996 May; 81(5):1711-9. PubMed ID: 8626821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to bromocriptine in prolactinomas.
    Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transsphenoidal microsurgical results of female patients with prolactinomas.
    Ikeda H; Watanabe K; Tominaga T; Yoshimoto T
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1621-5. PubMed ID: 23498159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests.
    Webster J; Page MD; Bevan JS; Richards SH; Douglas-Jones AG; Scanlon MF
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):35-44. PubMed ID: 1559298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases.
    Akin S; Isikay I; Soylemezoglu F; Yucel T; Gurlek A; Berker M
    Acta Neurochir (Wien); 2016 May; 158(5):933-42. PubMed ID: 26970763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment and long-term follow-up results of prolactin secreting pituitary adenomas.
    Scamoni C; Balzarini C; Crivelli G; Dorizzi A
    J Neurosurg Sci; 1991; 35(1):9-16. PubMed ID: 1890464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.